作者 | RAYYYY 编辑 | 小白 2025年上半年，A股市场在政策与基本面博弈中呈现震荡格局，公募基金行业则交出了一份颇具看点的半年度成绩单。 Choice数据显示，截至7月1日，全市场管理规模前十的基金经理均被指数型产品掌舵人占据，华泰柏瑞基金柳军以4120.1亿元的庞大规模稳坐头把交椅， 截至9月底，柳军现任基金总规模高达4669.8亿元，增长明显。 而在业绩上，汇添富基金的张韡成为最大黑马，其管理的汇添富香港优势精选A以86.48%的收益率夺冠，大幅跑赢市场，该基金今年以来收益更是高达 159%。 指数军团占据半壁江山，沪深300ETF规模最大 行业主线行情历来是"造神"利器。 01规模居前基金经理多数手握指数基金 2025年上半年，公募基金行业管理规模争夺战呈现新格局。Choice数据显示，管理规模前十的基金经理名单中，沪深300ETF管理者已占据绝对主导地 位。 | | 管理规模TOP 20的百亿基金经理 | | | | --- | --- | --- | --- | | 名称 | 管理基金数 | 管理规模 | 基金公司 | | 柳军 | 12 | 4120.09亿 | 华泰柏瑞基金 | | ...

Core Viewpoint - The A-share market has shown a "slow bull" trend in the first three quarters of this year, with significant contributions from the TMT (Technology, Media, and Telecommunications) sector, particularly in AI, robotics, and semiconductors. Active equity fund managers who actively position in new directions have performed well, but the volatility in popular sectors and events like the "tariff shock" in early April have impacted their ability to manage drawdowns, affecting investor experiences [4]. Summary by Category Overall Performance of Active Equity Fund Managers - In the first three quarters of this year, there are 1,698 active equity fund managers with an average return of 34.08% and a median return of 30.45%. The average drawdown is -13.93%, with a median of -13.05% [4][5]. - Fund managers managing over 100 billion yuan have the highest median returns at 36.79%, but also face larger drawdowns [5]. Performance by Management Scale - **Over 100 Billion Yuan**: 80 managers, median return 36.79%, median drawdown -14.13%. Top performers include Zhang Wei from Huatai-PineBridge and Ge Lan from China Europe Fund, both heavily invested in the pharmaceutical sector [6][7]. - **50-100 Billion Yuan**: 130 managers, median return 35.28%, median drawdown -13.28%. Top performers include Zheng Ning from Zhongyin Fund, with a return of 95.01% [9][10]. - **20-50 Billion Yuan**: 275 managers, median return 32.82%, median drawdown -13.08%. Top performers include Dan Lin from Yongying Fund, with a return of 97.40% [13][14]. - **Below 20 Billion Yuan**: 1,213 managers, median return 29.46%, median drawdown -12.95%. Top performers include Wang Chao from Fortune Fund, with a return of 93.31% [16]. Notable Fund Managers - **Zhang Wei**: Achieved a return of 69.62% with a maximum drawdown of -10.01%, managing six funds [7][8]. - **Zheng Ning**: Focused on innovative drugs, achieving a return of 95.01% with a maximum drawdown of -13.06% [10][12]. - **Dan Lin**: Achieved a return of 97.40% with a maximum drawdown of -12.88% [14]. - **Zhao Longlong**: Managed to achieve a return of 62.08% with the smallest drawdown of -9.51% among his peers [15]. Investment Focus - Fund managers are increasingly focusing on sectors such as innovative pharmaceuticals and high-end medical devices, with a notable emphasis on the potential of Chinese innovative drugs in international markets [8][10].

Core Insights - The A-share market has shown a "slow bull" trend in the first three quarters of this year, with significant contributions from the TMT sector, particularly in AI, robotics, and semiconductors [1] - Active equity fund managers have performed well, but the volatility in popular sectors and events like the "tariff shock" in early April have impacted their ability to manage drawdowns [1] - The average return for active equity fund managers this year is 34.08%, with a median return of 30.45%, while the average drawdown is -13.93% and the median drawdown is -13.05% [1][3] Fund Manager Performance by Management Scale Over 100 Billion - Among the 80 active equity fund managers with over 100 billion in management scale, the median return is 36.79% and the median drawdown is -14.13% [3] - Notable fund managers include Zhang Wei from Huatai-PineBridge and Ge Lan from China Europe Fund, both heavily invested in the pharmaceutical sector [3][4] 50-100 Billion - In the 50-100 billion category, 130 fund managers have a median return of 35.28% and a median drawdown of -13.28% [8] - The top performer is Zheng Ning from Bank of China Fund, achieving a return of 95.01% with a maximum drawdown of -13.06% [9] 20-50 Billion - For managers with 20-50 billion in assets, the median return is 32.82% and the median drawdown is -13.08% [10] - The top three fund managers include Dan Lin from Yongying Fund, Jin Xiaofei from Penghua Fund, and Zhao Longlong from Morgan Fund [12] Below 20 Billion - In the category of managers with less than 20 billion, the median return is 29.46% and the median drawdown is -12.95% [15] - The top three fund managers are Wang Chao from Fortune Fund, Qi Zhen from Huabao Fund, and Liu Haixiao from Haifutong Fund [15]

Group 1 - The article highlights the increasing prominence of female fund managers in the public fund sector, with women comprising 26.81% of the total 3,868 fund managers as of September 9, 2025 [1] - Among female fund managers, those with over 10 years of experience have a performance threshold of 29.65% to be in the top 10 this year [2] - The top-performing female fund manager, Zhou Sicong from Ping An Fund, achieved a return of 90.02% and manages four funds with a total scale exceeding 30 billion [4] Group 2 - Guo Lan from China Europe Fund leads in management scale among the top female fund managers, with nearly 40 billion in assets and a return of 38.66% [5] - The article notes that 304 female fund managers manage over 100 billion, with 72 managing over 500 billion, indicating a significant presence in the market [6] - Cai Kaer from Fortune Fund achieved the highest return of 40.99% this year, managing approximately 588 billion across 13 funds [8] Group 3 - The top 20 female active equity fund managers have a performance threshold of 53.49% this year, with Zhou Shanshan from交银施罗德基金 leading at 93.45% [9][13] - Zhou Shanshan's fund focuses on multiple asset classes and has significant holdings in the computing power sector, with her top stock, Xin Yisheng, rising by 81.97% [13] - The article emphasizes the strong performance of female fund managers in the context of a favorable A-share market this year [9]

金融界2025年8月21日消息，中欧医疗创新股票A(006228) 最新净值1.7589元，增长1.45%。该基金近1个 月收益率7.35%，同类排名796|1025；近6个月收益率47.02%，同类排名31|986；今年来收益率69.16%， 同类排名25|976。 中欧医疗创新股票A股票持仓前十占比合计64.06%，分别为：三生制药（8.99%）、科伦博泰生 （8.52%）、康方生物（8.20%）、药明合联（6.98%）、药明生物（6.04%）、百利天恒（5.89%）、药 明康德（5.63%）、凯莱英（5.21%）、新诺威（4.61%）、恒瑞医药（3.99%）。 公开资料显示，中欧医疗创新股票A基金成立于2019年2月28日，截至2025年6月30日，中欧医疗创新股 票A规模48.74亿元，基金经理为葛兰。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活 ...

Core Viewpoint - The A-share market has shown a clear bullish trend in 2023, with significant index breakthroughs, leading to impressive performance from many equity fund managers [4][5]. Group 1: Fund Manager Performance - As of August 15, 2023, there are 1,794 public fund managers with performance data, with the majority being new generation managers, achieving an average return of 20.68% for their equity funds [5]. - The performance of fund managers is categorized into three generations: - New Generation (less than 5 years): 901 managers, average return of 20.68% [5]. - Middle Generation (5-10 years): 635 managers, average return of 18.09% [5]. - Old Generation (10 years and above): 258 managers, average return of 16.78% [5]. - The total assets under management (AUM) for these fund managers amount to 55,735.04 billion [5]. Group 2: Top Fund Managers - The top five fund managers from the new generation include: - Liang Furui from Changcheng Fund with a return of 137.72% and AUM of approximately 1.1 billion [6][8]. - Chu Kefa and Ren Jie from Yongying Fund with returns of 122.30% and 108.97% respectively [6][9]. - The top five fund managers from the middle generation include: - Leng Wenpeng from CITIC Construction Investment Fund with a return of 104.73% and AUM of nearly 300 million [10][12]. - The top five fund managers from the old generation include: - Zhou Sicong from Ping An Fund with a return of 90.96% and AUM exceeding 3 billion [13][15]. Group 3: Investment Strategies - Liang Furui employs a unique three-cycle strategy focusing on demand and matching companies with demand cycles, particularly in the innovative drug sector [8]. - Chu Kefa combines quantitative risk control with active stock selection, favoring leading commercial companies and those with technological breakthroughs [9]. - Leng Wenpeng focuses on "specialized, refined, unique, and innovative" companies listed on the Beijing Stock Exchange [12]. - Zhou Sicong emphasizes a three-dimensional screening approach for innovative drug investments, predicting significant industry growth in 2025 [16].

金融界2025年8月18日消息，中欧医疗创新股票A(006228) 最新净值1.8118元，增长0.66%。该基金近1个 月收益率9.23%，同类排名152|437；近6个月收益率65.81%，同类排名13|420；今年来收益率74.25%， 同类排名13|420。 中欧医疗创新股票A股票持仓前十占比合计64.06%，分别为：三生制药（8.99%）、科伦博泰生 （8.52%）、康方生物（8.20%）、药明合联（6.98%）、药明生物（6.04%）、百利天恒（5.89%）、药 明康德（5.63%）、凯莱英（5.21%）、新诺威（4.61%）、恒瑞医药（3.99%）。 公开资料显示，中欧医疗创新股票A基金成立于2019年2月28日，截至2025年6月30日，中欧医疗创新股 票A规模48.74亿元，基金经理为葛兰。 来源：金融界 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中 ...

金融界2025年8月15日消息，中欧医疗创新股票A(006228) 最新净值1.8000元，增长1.85%。该基金近1个 月收益率16.51%，同类排名29|406；近6个月收益率67.44%，同类排名13|392；今年来收益率73.11%， 同类排名13|392。 中欧医疗创新股票A股票持仓前十占比合计64.06%，分别为：三生制药（8.99%）、科伦博泰生 （8.52%）、康方生物（8.20%）、药明合联（6.98%）、药明生物（6.04%）、百利天恒（5.89%）、药 明康德（5.63%）、凯莱英（5.21%）、新诺威（4.61%）、恒瑞医药（3.99%）。 公开资料显示，中欧医疗创新股票A基金成立于2019年2月28日，截至2025年6月30日，中欧医疗创新股 票A规模48.74亿元，基金经理为葛兰。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活配 ...

金融界2025年8月12日消息，中欧医疗创新股票A(006228) 最新净值1.6867元，下跌1.36%。该基金近1个 月收益率14.93%，同类排名75|1022；近6个月收益率61.44%，同类排名25|986；今年来收益率62.21%， 同类排名24|976。 中欧医疗创新股票A股票持仓前十占比合计64.06%，分别为：三生制药（8.99%）、科伦博泰生 （8.52%）、康方生物（8.20%）、药明合联（6.98%）、药明生物（6.04%）、百利天恒（5.89%）、药 明康德（5.63%）、凯莱英（5.21%）、新诺威（4.61%）、恒瑞医药（3.99%）。 公开资料显示，中欧医疗创新股票A基金成立于2019年2月28日，截至2025年6月30日，中欧医疗创新股 票A规模48.74亿元，基金经理为葛兰。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活 ...

金融界2025年8月7日消息，中欧医疗创新股票A(006228) 最新净值1.6940元，下跌3.58%。该基金近1个 月收益率16.92%，同类排名25|614；近6个月收益率60.72%，同类排名16|591；今年来收益率62.92%， 同类排名17|589。 中欧医疗创新股票A股票持仓前十占比合计64.06%，分别为：三生制药（8.99%）、科伦博泰生 （8.52%）、康方生物（8.20%）、药明合联（6.98%）、药明生物（6.04%）、百利天恒（5.89%）、药 明康德（5.63%）、凯莱英（5.21%）、新诺威（4.61%）、恒瑞医药（3.99%）。 公开资料显示，中欧医疗创新股票A基金成立于2019年2月28日，截至2025年6月30日，中欧医疗创新股 票A规模48.74亿元，基金经理为葛兰。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活配置 ...